公开(公告)号：US20220275360A1

公开(公告)日：2022-09-01

申请号：US17058124

申请日：2019-05-31

Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Inventor： Dong-Sik KIM ,  Mi Jung LEE ,  Mi Young OH ,  Hye-Ji CHOI ,  Gil-Jung KIM ,  Shin A JANG ,  Ae Rin YOON

IPC: C12N15/10 ,  C07K16/00 ,  C07K16/28

Abstract: The present invention relates to a novel antibody library and an antibody-screening method using same. Having a human sequence-derived specific VH or VL scaffold, the antibody library according to the present invention exhibits high thermodynamic stability and enjoys the advantages of allowing high soluble expression as well as reversible folding. In addition, the antibody according to the present invention includes a variety of rationally controlled CDRs so as to exhibit high specificity and high affinity to all antigens and thus can be advantageously used for selecting an adequate candidate antibody against a target antigen.

公开(公告)号：US20180030151A1

公开(公告)日：2018-02-01

申请号：US15553292

申请日：2015-12-29

Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Inventor： Dong-Sik KIM ,  Mi Jung LEE ,  Jae Chan PARK ,  Sumin LEE ,  Heechun KWAK ,  SungHo HWANG ,  Hyung-Kwon LIM ,  Kisu KIM ,  Young Seoub PARK ,  Junhong JEONG ,  Ki Joon CHO

IPC: C07K16/38

CPC classification number: C07K16/38 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/72 ,  C07K2317/92

Abstract: The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.